These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8695868)

  • 1. Defective lymphocyte glycosidases in the macrophage activation cascade of juvenile osteopetrosis.
    Yamamoto N; Naraparaju VR; Orchard PJ
    Blood; 1996 Aug; 88(4):1473-8. PubMed ID: 8695868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D3-binding protein as a precursor for macrophage activating factor in the inflammation-primed macrophage activation cascade in rats.
    Yamamoto N; Naraparaju VR
    Cell Immunol; 1996 Jun; 170(2):161-7. PubMed ID: 8660814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells.
    Yamamoto N; Kumashiro R
    J Immunol; 1993 Sep; 151(5):2794-802. PubMed ID: 8360493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A defect in beta-galactosidase of B lymphocytes in the osteopetrotic (op/op) mouse.
    Yamamoto N; Naraparaju VR
    Immunol Lett; 1996 Apr; 50(1-2):35-40. PubMed ID: 8793557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization.
    Yamamoto N; Naraparaju VR
    Immunol Cell Biol; 1998 Jun; 76(3):237-44. PubMed ID: 9682967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes.
    Yamamoto N; Homma S
    Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8539-43. PubMed ID: 1924312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of Gc protein-derived macrophage activating factor (GcMAF) and its structural characterization and biological activities.
    Mohamad SB; Nagasawa H; Uto Y; Hori H
    Anticancer Res; 2002; 22(6C):4297-300. PubMed ID: 12553073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of beta-galactosidase of B lymphocytes and sialidase of T lymphocytes in inflammation-primed activation of macrophages.
    Naraparaju VR; Yamamoto N
    Immunol Lett; 1994 Dec; 43(3):143-8. PubMed ID: 7721326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A defect in inducible beta-galactosidase of B lymphocytes in the osteopetrotic (mi/mi) mouse.
    Yamamoto N; Naraparaju VR
    Immunology; 1996 Aug; 88(4):604-10. PubMed ID: 8881764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A defect in the inflammation-primed macrophage-activation cascade in osteopetrotic rats.
    Yamamoto N; Lindsay DD; Naraparaju VR; Ireland RA; Popoff SN
    J Immunol; 1994 May; 152(10):5100-7. PubMed ID: 8176226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural definition of a potent macrophage activating factor derived from vitamin D3-binding protein with adjuvant activity for antibody production.
    Yamamoto N
    Mol Immunol; 1996 Oct; 33(15):1157-64. PubMed ID: 9070663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural modification of serum vitamin D3-binding protein and immunosuppression in AIDS patients.
    Yamamoto N; Naraparaju VR; Srinivasula SM
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1373-8. PubMed ID: 8573395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the Gc-derived macrophage-activating factor precursor (preGcMAF) on phagocytic activation of mouse peritoneal macrophages.
    Uto Y; Yamamoto S; Takeuchi R; Nakagawa Y; Hirota K; Terada H; Onizuka S; Nakata E; Hori H
    Anticancer Res; 2011 Jul; 31(7):2489-92. PubMed ID: 21873164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Galactosidase treatment is a common first-stage modification of the three major subtypes of Gc protein to GcMAF.
    Uto Y; Yamamoto S; Mukai H; Ishiyama N; Takeuchi R; Nakagawa Y; Hirota K; Terada H; Onizuka S; Hori H
    Anticancer Res; 2012 Jun; 32(6):2359-64. PubMed ID: 22641675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of vitamin D binding protein-macrophage activating factor and colony-stimulating factor-1 on hematopoietic cells in normal and osteopetrotic rats.
    Benis KA; Schneider GB
    Blood; 1996 Oct; 88(8):2898-905. PubMed ID: 8874186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).
    Yamamoto N; Suyama H; Yamamoto N; Ushijima N
    Int J Cancer; 2008 Jan; 122(2):461-7. PubMed ID: 17935130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF.
    Yamamoto N; Suyama H; Nakazato H; Yamamoto N; Koga Y
    Cancer Immunol Immunother; 2008 Jul; 57(7):1007-16. PubMed ID: 18058096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deglycosylation of serum vitamin D3-binding protein leads to immunosuppression in cancer patients.
    Yamamoto N; Naraparaju VR; Asbell SO
    Cancer Res; 1996 Jun; 56(12):2827-31. PubMed ID: 8665521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of vitamin D3-binding protein in activation of mouse macrophages.
    Yamamoto N; Naraparaju VR
    J Immunol; 1996 Aug; 157(4):1744-9. PubMed ID: 8759764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor.
    Yamamoto N; Naraparaju VR
    Cancer Res; 1997 Jun; 57(11):2187-92. PubMed ID: 9187119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.